MECR

Across TCGA pan-cancer cohorts, MECR mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MECR’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MECR mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MECR is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where MECR tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MECR mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.813	<.001	12	view →
HNSC	All	II,III,IV	−0.540	<.001	12	view →
LUAD	Female	II,III,IV	+0.396	<.001	8	view →
COAD	All	II,III,IV	+0.128	.007	3	view →
LSCC	All	All	+0.097	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MECR–CCRCC

Open the CCRCC breakdown →